1AD Investor Presentation
Released
Released
Announcement PDF
COMMERCIALISING
CELLULAR
IMMUNOTHERAPIES
“EAST TO WEST”
ADALTA LIMITED (ASX:1AD)
|
INVESTOR PRESENTATION |
JULY 2025
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 1
IMPORTANT NOTICE & DISCLAIMER
Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular
rate of return or performance, nor do they guarantee the repayment of capital.
This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the
investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective
investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and
consult an investment advisor if necessary.
This presentation may contain forward-looking statements regarding the potential of the Company’s projects and interests and the development and
therapeutic potential of the company’s research and development. Any statement describing a goal, expectation, intention or belief of the company is
a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human
therapeutics and the financing of such activities.
There is no guarantee that the Company’s research and development projects and interests (where applicable) will receive regulatory approvals or
prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation.
As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research
and development programs referred to in this presentation.
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 2
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS
“East to West” cellular immunotherapy strategy for growth: AdCella
AdAlta is a clinical
stage biotech:
• Growth powered by
“East to West”
cellular
immunotherapy
strategy
• Monetising other
valuable assets
In-license next generation clinical stage assets from Asia, establish
Western manufacturing and generate clinical data for on-licensing
Leverages our unique skills, regional ecosystem and business model to
create a leader in cellular immunotherapy for solid cancer patients
Bridges the gap between Asian innovation and Western biopharma
companies (and patients who can benefit from them)
Creates a series of capital efficient, short investment horizon assets
with frequent clinical milestones
Other valuable pipeline assets for monetisation
Builds pipeline above first in class anti-fibrotic protein, AD-214, with
strategic partners sought for continued development into Phase II outside
the company, and world first pan-strain inhibitor of malaria parasites,
WD-34, with strategic partners sought to advance to proof of concept
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 3
“EAST TO WEST” STRATEGY
CENTRAL TO ADALTA’S GROWTH
AdCella Pty Ltd, an AdAlta company
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 44
“EAST TO WEST” STRATEGY OVERVIEW
AdCella has clear
aspirational growth targets
for its
“East to West” strategy
By end 2025
From 2026
Substantial value inflection potential by bringing “Eastern” cellular
immunotherapy innovations to “Western” regulated markets
Exclusive focus on T cell therapies for solid cancers targets less
competitive markets while utilising proven cellular immunotherapies
Combining Asia's innovative T cell therapies for solid cancers and
Australia's manufacturing advantages leverages unique regional benefits
Robust asset selection process yielding access to first/best in class,
highly differentiated products with clinical evidence of safety and efficacy
Three assets
secured
One asset into
clinical trials
each year
Capital light model offers quick ROI potential: a single clinical trial to
value inflection using external capital and AdAlta product management
Highly scalable to become industry leader through systematic product
licensing and pipeline expansion opportunities
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 5
RATIONALE FOR OUR STRATEGY
Market opportunity
90%
34%
$20.3B
50%
2
61%
Cancers that are solid
tumours and remain
underserved by cellular
immunotherapies
CAGR of cellular
immunotherapy market and
market size by 20281
Revenue estimated to be
generated from solid
tumours by 2030;2 recent
FDA approvals setting stage3
Asia leads in total clinical
trials,4 providing a unique
innovation pool in which
AdAlta can lead
Competitive advantage
•
Networks: Asia's rich innovation,
Australia's clinical and manufacturing
ecosystem, AdAlta's pre-IND to clinical
skills
Exclusive access to first assets
Exclusive access to initial three assets from
pipeline of 10 high-potential therapies
•
Strategic sourcing: Disciplined asset
selection of highly differentiated assets
with clinical data in solid cancers
First in class armored CAR-T
for lung, gynaecological,
pleural and peritoneal
cancers
•
Unique value proposition: asset
financing for partners enables more
valuable exit; “East to West” reduces risk
for buyers
First-in-class CAR-T for
advanced colorectal and
gastric
•
•
Capital-light: modest investment
leveraged with outside investment to
achieve a single inflection before exit
Scalable: replicable across multiple
assets
Pipeline of more than 10
assets being monitored
Platform technology access
being evaluated
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 6
1. Grandview Research, “T-cell Therapy Market Size, Share & Trends Analysis” Feb 2021; 2. Polaris Market Research, “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report”, June 2021 2. Alliance for Regenerative Medicine, Developer Data
Report Q3 2023; 3. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi; https://www.fda.gov/vaccines-blood-biologics/aucatzyl 4. GlobalData, Pharma Intelligence Centre, Clinical Trials Database (accessed 5 April 2024)
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS
3
3
On-licensing:
Establish global
manufacturing network
and on-license to
commercialisation
partners. AdAlta and
partner share increased
value that partner could
not achieve on their own
In-license market leading
assets from Asia (“East”):
Low acquisition cost. By
financing to next inflection
point AdAlta acquires a
share of the asset at exit
1
2
Build value by transferring to “West” under AdAlta management:
Apply Western regulated manufacturing, obtain first Western regulated
clinical data in Australia to create substantial inflection point for big pharma;
managed by AdAlta and leveraged with third party investment
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 7
VALUE AT EXIT: PHASE I CAR-T LICENSING TRANSACTIONS
Deal stage
Lead indications
Total
value (US$m)
Upfront
(US$m)
MAGE-A4 targeting TCR T
cell therapy
Phase 2
(ongoing; global)
Head & neck cancer
665
85
Nov-23
DLL3 targeting autologous
CAR-T cell therapy
Phase 1
(ongoing; US)
SCLC, LCNEC
1,110
100
May-23
CD20 and CD19/20directed autologous CAR-T
cell therapy
Phase 1
(completed; China)
B-cell NHL,
Follicular lymphoma, mantle
cell Lymphoma, DLBCL
n/a
245
Jan-23
CART-ddBCMA
Phase 2
(ongoing; US)
Multiple myeloma
n/a
325
Dec-22
Anti-BCMA CAR-T cell
therapy
P1b
(ongoing; Israel)
Multiple myeloma
34.55
1.5
Dec-20
Mesothelintargeted autologous
and allogeneic CAR-T
cell therapy
Phase 1
(ongoing for autologous therapy;
US)
Peritoneal /
pleural mesothelioma
670
60
MEDIAN
667.5
92.5
Date
Drug(s)
May-24
Licensor
Licensee
Global top 25 oncology pharma companies investing in
autologous cell therapy (licensing, M&A, CVC)
5y
72%
2y
44%
AdAlta Limited (ASX:1AD) | Investor Presentation |
Source: Company press releases, GlobalData; Beacon Intelligence
July 2025 | 8
PROGRESS AND POTENTIAL
Asset acquisition stream – exclusive access secured
• Technical and on-site diligence, development planning complete
• On track for first asset license Q3 2025
• Discussions opening with clinical trial sites
We are here
today
First IND
approval (F)
Financing stream
• Seed financing from SYNBV, subject to closing conditions
• On going discussions with global financial partners – generally
conditional on securing first license
“East to West” cell
therapy strategy
announced;
MoU with SYNBV
10 assets in
diligence
Consultant CMO
appointed
Three high value
Exclusive access 2 assets selected
for
licensing
assets
secured (F)
to three assets
First transaction
(term sheets
targeted
Q3 2025 (F)
signed, exclusive
negotiation
period)
End-2025
Apr-2024
Carina Biotech
collaboration to
develop i-body®
bi-specific CAR-T cells
May-2024
Preferred
manufacturing
partnership with
CTPL
Jul-2024
Oct-2024
1st non-binding
in-licensing
term sheet
Oct-2024
2028+
2026+
2H-2025
Initiate one new
clinical trial per year
(target)
1H-2025
Aug-2021
Australian clinical
trial data facilitates
pivotal studies,
licensing agreements
and asset sales
Negotiating platform
technology access
More term sheets in
development; multiple
products being
monitored
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 9
ASSET #1: FIRST-IN-CLASS ARMOURED X-CAR-T
Product #1
Armoured-X-CAR-T
What is the
product?
Which cancers
could it address?
Why does it stand
out from the
competition?
Anti-PD1 secreting CAR-T manufactured using 30h virus
free process
Advanced, solid cancer
patient: sustained response
to armored-CAR-T
Lung, mesothelioma, ovarian, cervical, pancreatic,
colorectal
• First armoured CAR-T against X
• Anti-PD1 secretion addresses known tumour
resistance mechanism, bystander effect on all
immune cells
• Demonstrated activity beyond mesothelioma
X-CAR-T
• Rapid, virus free manufacturing reduces COGS,
patient turnaround time
• Response and survival in advanced mesothelioma
superior to current 2L SoC
What is its
development
status?
3 China IIT studies (n=33)
China Phase 1 IND approval
US ODD (mesothelioma), pre-IND meeting
Abbreviations: 2L – second line therapy; SoC – standard of care; IND – Investigational New Drug; ODD – Orphan Drug Designation;
IIT – Investigator Initiated Trial; ORR – overall response rate; CR – complete response; PR – partial response; mPFS – median
progression free survival; mOS – median overall survival
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 10
ASSET #2: FIRST-IN-CLASS Y-CAR-T
Pancreatic tumor B4T2-001
cleared
bypancreatic
Y-CAR-T
in re-challenge model
CAR-T
tumor re-challenge
Product #2
Y-CAR-T
⁻ B4T2-001 CAR-T cells were NOT readministered upon re-engraftment
• Ten days after the tumor re-engraftment, the
Epithelial solid cancers incl. colorectal, lung and gastric
tumors in all animals started to be eliminated
• Novel target Y – superior tumour targeting to other
family members
Why does it stand
out from the
competition?
Tumor Volume mm3
Which cancers
could it address?
IP without lymphodepletion
• Multi-dosing without lymphodepletion – enabled by
platform technology
• IV and IP administration
• Activates at high antigen density only, minimises off
tumour targeting
• Safety switch enables turning off CAR-T
Untransduced T Cell Control
Y-CAR-T treated
B4T2-001
CAR-T
Y-CAR-T CAR-T
blood level
(RHS)
B4t2-001
Blood
Level (by FACS)
CAR-T
B4T2-001
Tumor
engraftment +Infusion
CAR-T
2 China IIT studies (n=9)
Extensive pre-clinical research in China
Platform and pipeline add-on potential
Tumor
Tumor Re-engraftment
engraftment
only
NSG mice
n=5
Post CAR-T Dosing
Complete resolution of malignant ascites in Stage
IV gastro-intestinal cancer patient
5,000
5,000
• Multiple bi-specific follow-on products
What is its
development
status?
Blood Exposure:
CAR T cell /100ul Blood
What is the
product?
• We conducted a tumor re-challenge study in which
mice were re-engraftment with tumor cells after
having experienced a complete response to a
primary tumor using B4T2-001 CAR-T cells
Novel target CAR-T with safety switch, administered exhibited
IV, superior persistence and protective
capacity in vivo
3,000
1,000
Day -3
Day 1 (CART)
Day 9
Abbreviations: 2L – second line therapy; SoC – standard of care; IND – Investigational New Drug; ODD – Orphan Drug Designation;
IIT – Investigator Initiated Trial; ORR – overall response rate; CR – complete response; PR – partial response; mPFS – median
progression free survival; mOS – median overall survival
Day 11
50
0
Day 18
Day 22
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 11
AD-214: A NEW APPROACH
TO FIBROSIS
AVAILABLE FOR PARTNERING
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 12
12
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214
Investment to date has built strong value proposition
First in class molecule
targeting established mode
of action in fibrotic disease
Pre-clinical efficacy in
multiple animal models of
fibrotic disease – derisks
clinical studies in US$b
indications
Phase I successfully
completed (two studies)
Clinically viable dosing
regimen
Strong intellectual property,
regulatory position
✓
Competitively positioned as only antibody-like
therapeutic entering late-stage development pipeline
Key Priority: Seek out-licensing or third-party investment to
unlock next level of value
Advisors engaged; pipeline of active discussions
Product development priorities
✓
Led by Idiopathic Pulmonary Fibrosis (IPF): TAM
US$4.3b
1. Generate clinical proof of concept (efficacy)
✓
Multiple US$b indication potential: kidney, eye, cancer
• Demonstrate efficacy signals in patients
• IV or SC administration
✓
Well tolerated, evidence of target binding
✓
Intravenous (IV) every 2 weeks established
✓
Subcutaneous (SC) every week feasible
✓
Models linking PK/PD and preclinical efficacy to
establish dose
✓
Patents protecting asset to 2036 and beyond
✓
US FDA Orphan Drug Designation for IPF
✓
10-12 years market exclusivity (US, EU)
• Substantially increases number of potential licensing partners
Design and execute clinical strategy in IPF patients
2. Develop market preferred formulation
• Weekly SC preferred over two weekly IV
• Enhanced market share, reduced COGS
• Achieves commercial ready COGS
Develop formulation, integrate into clinical trials
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 13
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET
Many other fibrosis market opportunities2
IPF market is underserved today
•
Poor efficacy: Existing therapies slow but do not halt
progression and do not significantly extend life expectancy
•
Side effects: Their side effects result in 30-50% of patients
discontinuing therapy after one year
•
Expensive: US$136,000 pa cost of treatment in US
Global IPF sales (US$ billion)¹
8-year CAGR: 4.7%
Lung
US$4b
5.11
Kidney
US$10b
Eye
US$15b
Per Cancer
US$1b
4.30
3.55
New drivers of incidence may include:
2019
2022
•
Re-emergence of silicosis
•
Long COVID3
2027E
AdAlta Limited (ASX:1AD) | Investor Presentation |
1. GlobalData, Idiopathic Pulmonary Fibrosis: Competitive Landscape, April 2023; Roche and Boehringer Ingelheim financial reports,AdAlta analysis 2. GlobaData,
disease analysis reports 3. PM George, et al, “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy”, Lancet published online May 15, 202
July 2025 | 14
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS
Transaction
Upfront payment to
licensor
Contingent
milestones
Clinical Phase at
transaction
Aug-22
License
US$100m
US$600m
2 complete
Apr-20
Acquisition
US$45m
Not disclosed
2a complete
Nov-19
Acquisition
US$390m
US$1,000m
2 complete
Jan 23
China only license
US$76m
US$240m
2 underway
Feb 23
Acquisition
US$425m
N/A
2a underway
Jan 25
License
US$99m
US$687m
2 (Ready)
Nov-21
Acquisition
US$353m
N/A
2 (Ready)
Nov-20
License
€25m
€295m
2 (Ready)
Sep-21
License
US$152m
US$450m
2 (Ready)
Feb-21
License
Not disclosed
US$517.5m
1 underway
Jul-19
License
€45m
€1,100m
1 underway
Oct-22
Acquisition
US$255m
Not disclosed
Pre-clinical
(+ platform)
Date
Licensor/target
Licensee/acquirer
AD-214 is
Phase 2 (ready)
AdAlta Limited (ASX:1AD) | Investor Presentation |
Source: Company press releases, GlobalData; Beacon Intelligence
July 2025 | 15
WD-34 I-BODY: A POTENTIAL
BREAKTHROUGH IN MALARIA
AVAILABLE FOR PARTNERING
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 16
16
WORLD FIRST PAN-SPECIES HIGH POTENCY ANTI-MALARIAL
WD-34 i-body has potential to transform malaria treatment
Malaria remains a
global killer
Meaningful global
market
Limitations of
current therapies
WD-34 i-body
offers a potential
breakthrough
Opportunity
✓
247 million cases, 619,000 deaths in 20211
✓
Re-emerging in US and EU2
✓
New markets in related tick-borne diseases eg Babeziosis
✓
US$990 million market for anti-malarial drugs4 (travellers, deployed
personnel
✓
Market limited by poor efficacy, cost of therapies in emerging markets
✓
Small molecules: rapid development of resistance and inconvenient dosing
regimens
✓
Antibodies: typically strain specific or limited inhibition
✓
Vaccines: limited efficacy; antigen variability
✓
Novel discovery strategy targeted a conserved region of AMA-1 protein
✓
Recognises AMA1 from multiple malaria (Plasmodium) species as well as
Babesia and Toxoplasma
✓
High potency inhibition of multiple life cycle stages
✓
IP filed
✓
Long acting, single dose (3-6mo) prophylaxis for deployed personnel,
travellers
✓
Seasonal prophylaxis for children in endemic malaria regions
✓
Novel method of antigen identification for more effective vaccines
Strategy: seeking non-dilutive and commercial
partners to advance outside AdAlta
Active discussions to spin out asset
AMA1
PPM
WD-34
i-body®
Host red blood cell
Model of plasmodium falciparum malaria (PPM) with
AMA1 / RON2 protein complex and host erythrocyte 3
showing how WD-34 inhibits invasion via AMA1
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 17
1. World Health Organisation, World Malaria Report 2022, https://www.who.int/publications/i/item/9789240064898 2. https://publichealth.jhu.edu/2023/malarias-comeback-in-the-us and https://blogs.biomedcentral.com/bugbitten/2023/08/25/locallyacquired-malaria-in-europe-and-the-us/ 3. Adapted from Drew et al. Cell. Mol. Life Sci. 80, 74 (2023) using BioRender. 4. Grandview Research, “Anti-malarial Drugs Market Size, Share & Trends Analysis Report 2024-2030”.
CORPORATE
INFORMATION
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 18
18
CORPORATE SNAPSHOT
AdAlta Limited
Code
ASX:1AD
Market Capitalisation
$2.2m
Enterprise Value
$0.9m
Cash (30 June 2025)
$1.3m
Significant Shareholders
Sacavic Group
15.5%
Meurs Group
8.6%
Platinum International
Healthcare Fund
7.6%
~1,340 other shareholders
68.3%
Specialist in next-generation cell and protein
therapeutics for fatal diseases
Exclusive position on three "East-to-West" cell
therapy assets, with team and execution
network in place
Capital-light, highly scalable model with
numerous value inflection points in the rapidly
growing cellular immunotherapy market
AD-214, a new approach for fibrotic diseases,
(Phase 1 trials complete) and AMA1 i-body
first in class anti-malarial now available for
partnering
Attractive valuation (trading at cash value)
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 19
EXPERIENCED TEAM WITH GLOBAL REACH
Board
Paul MacLeman, DVM
Chair
Tim Oldham, PhD
CEO / Managing Director
Executive
Angus Tester, PhD
Senior Director Operations
Janette Dixon, DBA
“East-to-West” Strategy
AD-214: Fibrosis
Kevin Lynch
TBA - engaged
Prof Andrew Wilks
Joseph Tyler
Consultant CMO
Consultant CMO
VC Advisor
Consultant CMC Expert
Head of Business
Development
DHC secondment
Prof Tamera Corte
Head of Asset
Development
Michelle Burke
Independent Director
Clinical Advisory Board
Andrew O’Brien, PhD
Head of Corporate
Development
Steve Felstead
Dr David Fuller
Independent Director
Darryn Bampton
Director, Clinical and
Regulatory Operations
AdAlta has been
building capability for
its “East-to-West”
strategy
Clinical Advisory Board
Prof Toby Maher
Clinical Advisory Board
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 20
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED
“East to West” cellular
immunotherapy growth strategy
positioned for growth leveraging Asia
region and business model
advantages in high value, high growth
sector
Exclusive position on first three
assets for the “East to West” clinical
pipeline to create a leader in cellular
immunotherapy for solid cancer
patients
Experienced team and accessible
global network ready to execute a
diverse pipeline of opportunities
AD-214, available for partnering to
unlock value created, heading to
Phase II (US$4.3b IPF market),
substantially de-risked by Phase I
study clinical readouts
WD-34, available for partnering to
create additional value
Attractive valuation relative to
commercial potential of pipeline –
trading at cash value, potential for a
single transaction to materially
influence valuation
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 21
FOR MORE INFORMATION PLEASE CONTACT:
TIM OLDHAM
CEO & MANAGING DIRECTOR
+61 403 446 665
T.OLDHAM@ADALTA.COM.AU
IR@ADALTA.COM.AU
WWW.ADALTA.COM.AU
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 22
THE MARKET OPPORTUNITY
T cell solid cancer therapy: the next frontier for cellular immunotherapy
What is T-cell therapy?
Involves re-engineering and
turbo-charging patient’s
own immune cells to “see”
cancer
Living drug, single dose,
potentially curative
6 FDA-approved CAR-T
therapies since 2017
transformed blood cancer
outcomes, but so far only
for blood cancers
>US$2.6B earned
in 20221
Complete response rates:2
83% r/r pALL
51-65% r/r LBCL
78% r/r MM
In 2024, FDA approved two
T cell therapies for solid
cancer (melanoma,
sarcoma), opening the
much larger solid cancer
market segment3
50% of US$20.3B forecast
cellular immunotherapy
revenue for 20284
1. Company websites and financial filings
2. Kymriah, Yescarta and Carvytki prescribing information; r/r = relapsed/refractory; pALL – paediatric
acute lymphoblastic leukemia, LBCL = large B cell lymphoma, MM = multiple myeloma
3. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi;
https://www.fda.gov/vaccines-blood-biologics/aucatzyl
4. Grandview Research, “T-cell Therapy Market Size, Share & Trends Analysis” Feb 2021; Polaris Market
Research, “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report”, June 2021
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 23
ACCESSING QUALITY ASSETS FROM ASIA
Quality Asia cellular
immunotherapy pipeline,
barriers to reach West
“At JPM Week, biopharma
innovation from China and Asia
was the topic of conversation —
reshaping the global biopharma
landscape”4
Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western
experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty
transferring data and know-how, lack of patient diversity in clinical data and geopolitical challenges.1
Cellular immunotherapy developers 20232
(n = 1,104)
Europe
185
>50% of global ADC, bispecific
antibody and CAR-T clinical
pipeline is China originated5
US$500m Series A investments
in 3 China NewCos in first week
of 2025
30% of big pharm licensing deals
now involve a China biotech 5
North
America
439
Cellular immunotherapy clinical trials 2024 3
(n = 1,804)
RoW
31
41%
Developers
are from Asia
Pacific
Europe
162
Asia Pacific
449
North
America
583
RoW
41
61%
Clinical trials
are from Asia
Pacific
Asia Pacific
1,108
New CAR-T therapies from China doubled every year since 2014
1. Emerging Licensing Trends: Impact of Game Changing New Co’s” panel at 8th BCF Healthcare Conference, San Francisco, 12 January 2025 2. Alliance for Regenerative Medicine, Developer Data Report Q3 2023
3. GlobalData, Pharma Intelligence Centre, Clinical Trials Database (accessed 5 April 2024) 4. BioCentury, 23 January 2025 5. https://www.biopharmadive.com/spons/is-2025-the-chinese-year-of-biopharma/738274/
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 24
LEVERAGING ADCELLA’S COMPETITIVE ADVANTAGES
Process: asset sourcing discipline
• T cell therapies for solid cancers
• Differentiated, multi-functional
product design
• Clinical data in hand (safety,
efficacy)
• Manufacturable at scale
• Best/first-in-class potential
Place: network and ecosystem
• Tap Asian innovation; ongoing Asia
clinical trials leverage
• Utilise Australian translational and
manufacturing excellence
• Leverage Australian cost
advantage over US
Value: capital-light, risk managed
Highly
scalable
model
• AdAlta managed; JV/asset financed
• Defined investment in clinically
derisked asset
• Short time to value creation:
~3-year horizon per asset
• Leverage Australian R&D Tax
Incentive
Value: USP for partners
• Asset financing to ”Westernise”
• Generate important FDA regulated
clinical data, manufacturing site
• Partner maintains control of asset;
benefits from value inflection
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 25
1. FIRST-IN-CLASS ARMOURED X-CAR-T
Product design and differentiation
• First aPD1 armored X-CAR-T: targets known resistance mechanism enhancing potency of CAR-T, bystander T cells
• Non-viral vector transduction and rapid (30h) manufacturing process – lower cost, increased capacity
Advanced, solid cancer patient:
sustained response to armored-CAR-T
• Demonstrated activity beyond mesothelioma
Target market
Clinical data
• Mesothelioma, lung, ovarian, cervical, pancreatic,
colorectal cancers
• Advanced mesothelioma: ORR 63.5%; CR 9%; PR
54.5%; SD 36.4 %; mPFS 5 months; mOS > 40
months
• More than 1.5 million relapsed, refractory or
metastatic patients requiring second-line
treatment (2L) worldwide
• Europe is largest market for mesothelioma
• Substantially superior to 2L SoC on all measures
• Activity, confirmed response in other cancers eg
ovarian
• Safety management protocol maintains CRS at
Grade 1, most common SAEs are haematological
Competitive position
Development status
• Excellent target which has previously struggled to
advance beyond Phase II
• 3 China IIT’s in China (n = 33 advanced cancer
patients)
• Armoring provides potential to overcome lack of
potency of other CAR-Ts and modalities; bystander
effect on endogenous as well as CAR-T cells
• Phase 1 trial IND approved by China NMPA
• Big pharma focused on bispecifics, antibody drug
conjugates (ADCs): all at Phase I
• No directly competitive product >Phase II
• ODD from US FDA for mesothelioma
• Potential for further dose escalation identified
• Patent applications protecting CAR and aPD1
binders and transduction technology
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 26
2. FIRST-IN-CLASS Y-CAR-T
Product design and differentiation
• Novel target engages tumour and subset of immune cells to support engraftment, proliferation and persistence
• Can be multi-dosed with low/no lymphodepletion and administered IV and IP
• Selective activation at high antigen density, plus engineered safety switch
Target market
Clinical data
• Colorectal cancer and a wide range of epithelial solid
cancers including gastric and lung
• Activity in 9 heavily pre-treated patients, including
reduction/resolution of malignant ascites
• More than 1.5 million relapsed or refractory patients
worldwide each year
• 4/9 received multiple doses
• 130,000 3L colorectal cancer patients each year
Complete resolution of
malignant ascites in Stage IV GI
cancer patient
5,000
• Engraftment in 8/9, 5/5 without lymphodepletion
• Kill switch tested
3,000
• Typical CAR-T toxicity profile manageable with
tocilizumab
Competitive position
Development status
• Limited competitor products against this target
family; no CAR-T products against this target
• Compelling preclinical package in multiple difficult
tumor, rechallenge models
• This target most widely expressed of family in
cancer
• 2 China IITs (n=9 very advanced patients)
• Experienced, networked development team
• Demonstrated manufacturing on lower cost
Cocoon platform
• Western clinical centres already engaged
• Attractive bi-specific follow-on pipeline
5,000
1,000
• Potential for further dose escalation identified
• Patent applications protecting CAR binder, avoiding
lymphodepletion, method of optimising CAR
50
Day -3
Day 1 Day 9
(CAR-T)
0
Day 11 Day 18 Day 22
AdAlta Limited (ASX:1AD) | Investor Presentation |
July 2025 | 27
Share your feedback
Discover